A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia

Trial Profile

A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Mardepodect (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Jun 2008 Actual end date is added as Feb 2008 as reported by ClinicalTrials.gov.
    • 11 May 2008 Actual no of patients added as 35 as reported by ClinicalTria;s.gov.
    • 11 May 2008 Actual start date changed from Dec 2007 to Nov 2007 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top